<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are at high cardiovascular risk and require a global management targeting <z:hpo ids='HP_0000001'>all</z:hpo> risk factors </plain></SENT>
<SENT sid="1" pm="."><plain>Target values for blood pressure have been discussed in a previous paper </plain></SENT>
<SENT sid="2" pm="."><plain>The present clinical case summarizes the most important arguments concerning the choice of the target values for <z:chebi fb="105" ids="17234">glucose</z:chebi> control (glycated <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> or HbA1c) and <z:chebi fb="23" ids="18059">lipid</z:chebi> management </plain></SENT>
<SENT sid="3" pm="."><plain>As far as <z:chebi fb="105" ids="17234">glucose</z:chebi> control is concerned, the objective should be individually adjusted, based on the benefits/risks ratio, with a less stringent HbA1c level in presence of <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> and risk of severe <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>However, in absence of these two risks factors, the objective should be reinforced (HbA1c &lt; 7%), essentially to prevent or retard microangiopathic lesions </plain></SENT>
<SENT sid="5" pm="."><plain>As far as <z:chebi fb="23" ids="18059">lipid</z:chebi> management is concerned, the most crucial goal remains <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> lowering, with a target value &lt; 100 mg/dL in patients at high cardiovascular risk and &lt;70 mg/dL in patients at very high risk, according to the recent European guidelines </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">Dyslipidaemia</z:e> related to the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (hypertriglyceridaemia, <z:hpo ids='HP_0003233'>low HDL cholesterol</z:hpo>) may also represent a therapeutic target (non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>), although evidence is mostly missing in the literature </plain></SENT>
</text></document>